Fatal varicella zoster virus encephalitis in two patients following allogeneic hematopoietic stem cell transplantation

Clinical Transplantation

Volumn 19, Issue 4, 2005, Pages 566-570

  Hackanson, Björn ^a   Zeiser, Robert ^a   Bley, Thorsten A ^a   Pantazis, Georgios ^a   Huzly, Daniela ^a   Bertz, Hartmut ^a   Finke, Jürgen ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antiviral therapy; Encephalitis; Hematopoetic stem cell transplantation; Immunocompromised; Varicella zoster infection

Indexed keywords

ACICLOVIR; CYCLOSPORIN A; FLUDARABINE; FOSCARNET; HERPES ZOSTER IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; VIRUS ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; DRUG MEGADOSE; FATALITY; FEMALE; GRAFT VERSUS HOST REACTION; HEADACHE; HERPES ZOSTER; HERPES ZOSTER ENCEPHALITIS; HLA MATCHING; HUMAN; IMMUNE DEFICIENCY; LOW DRUG DOSE; MALE; MUSCLE RIGIDITY; NECK MUSCLE; NONHUMAN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; VACCINATION; VARICELLA ZOSTER VIRUS; VISUAL IMPAIRMENT;

ACYCLOVIR; AGED; ENCEPHALITIS, VARICELLA ZOSTER; FATAL OUTCOME; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS; MALE; MIDDLE AGED;

EID: 22244453744     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00382.x     Document Type: Article

References (22)

1. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994: 13: 277.
2. Koc Y, Miller KB, Schenkein DP et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000: 6: 44.
3. Ljungman P, Lonnqvist B, Ringden O, Skinhoj P, Gahrton G. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Nordic Bone Marrow Transplant Group. Bone Marrow Transplant 1989: 4: 613.
4. Sullivan KM, Dykewicz CA, Longworth DL et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology (Am Soc Hematol Educ Program) 2001: 392.
5. Gross G, Schofer H, Wassilew S et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003: 26: 277 (Discussion 291-293).
6. Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 2003: 59: 49.
7. Kanda Y, Mineishi S, Saito T et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001: 28: 689.
8. Tauro S, Toh V, Osman H, Mahendra P. Varicella zoster meningoencephalitis following treatment for dermatomal zoster in an alloBMT patient. Bone Marrow Transplant 2000: 26: 795.
9. Taylor-Wiedeman J, Brunell PA, Geiser C. Shehab ZM, Frierson LS. Effect of transfusions on serologic testing for antibody to varicella. Med Pediatr Oncol 1986: 14: 316.
10. Grant RM, Weitzman SS, Sherman CG, Sirkin WL, Petric M, Tellier R. Fulminant disseminated varicella zoster virus infection without skin involvement. J Clin Virol 2002: 24: 7.
11. Takaue Y, Okamoto Y, Kawano Y et al. Regeneration of immunity and varicella-zoster virus infection after high-dose chemotherapy and peripheral blood stem cell autografts in children. Bone Marrow Transplant 1994: 14: 219.
12. Peterslund NA, Esmann V, Ipsen J, Christensen KD, Petersen CM. Oral and intravenous acyclovir are equally effective in herpes zoster. J Antimicrob Chemother 1984: 14: 185.
13. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992: 165: 119.
14. Einsele H, Hebart H, Kauffmann-Schneider C et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000: 25: 757.
15. Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000: 25: 657.
16. Hata A, Asanuma H, Rinki M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002: 347: 26.
17. Fillet AM, Dumont B, Caumes E et al. Acyclovir-resistant varicella-zoster virus: phenotypic and genetic characterization. J Med Virol 1998: 55: 250.
18. Morfin F, Thouvenot D, De Turenne-Tessier M, Lina B, Aymard M, Ooka T. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 1999: 43: 2412.
19. Nikkels AF, Snoeck R, Rentier B, Pierard GE. Chronic verrucous varicella zoster virus skin lesions: clinical, histological, molecular and therapeutic aspects. Clin Exp Dermatol 1999: 24: 346.
20. Ida M, Kageyama S, Sato H et al. Characterization of acyclovir susceptibility and genetic stability of varicella-zoster viruses isolated during acyclovir therapy. J Dermatol Sci 2000: 23: 63.
21. Snoeck R, Andrei G, De Clercq E. Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs 1999: 57: 187.
22. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985: 152: 1172.